Comprehensive pharmacological approach to treatment of reactivation of Chagas disease in patients with HIV / AIDS

Abstract

Reactivation of Chagas Disease in patients HIV/AIDS with low counts LTCD4 is a problem that complicates management of both infections. There are currently two antiparasitic drugs properly documented efficacy in patients non-co-infected patients. However, there is little evidence and clinical experience regarding the efficacy and safety of an integral treatment in this group of patients, who are susceptible of suffering diverse adverse drug reactions and who have high mortality rates both in the short and long-term. In this article we describe the considerations (especially those related to adverse effects and possibility of pharmacological interactions) that must be taken into account during the combined antiretroviral, antichagasic and anticonvulsant treatment, as well as the most convenient treatment for patients described co- infected.